Breaking News

Almac Invests in Instrumentation at Spectroscopy Labs

Purchases an Agilent 6545XT AdvanceBio Q-TOF Mass Spectrometer and a Malvern Panalytical Empyrean X-Ray Powder Diffractometer.

By: Kristin Brooks

Managing Editor, Contract Pharma

Almac Sciences, a member of the Almac Group, has invested £500,000 in state-of-the-art instrumentation within its spectroscopy labs at its global headquarters in Craigavon, Northern Ireland.

Almac has purchased the new Agilent 6545XT AdvanceBio Q-TOF Mass Spectrometer and a Malvern Panalytical Empyrean X-Ray Powder Diffractometer.

The Craigavon labs house state-of-the-art Mass Spectrometers, X-Ray Powder Diffractometers as well as Nuclear Magnetic Resonance Spectrometers. These investments substantially increase the company’s capabilities to help solve complex analytical challenges and provide additional security for urgent analyses, additional processing capabilities, and data integrity controls to ensure increasing regulatory compliance.

Within the dedicated facility, equipped with advanced LC-MS, GC-MS, ICP-MS, XRPD and NMR instrumentation, spectrometry services include the quantitation of genotoxic impurities, trace elemental analysis, isotopic purity determinations, structure elucidation, analysis of peptides, proteins, glycoproteins and antibody products as well as polymorph screening, confirmation and quantitation of crystalline phases.

Dr. John Malone, Associate Director of Spectroscopy, Almac Sciences said, “The continued investment and growth in our spectroscopy laboratories underlines Almac’s commitment to providing the best analytical facilities for its customers and seamlessly meeting their needs.  We are delighted to offer our clients cutting-edge technology that supports their product safety imperative and accelerates the drug development cycle.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters